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INTRODUCTION 
Danazol (D), a 2-3 isoxazol derivative of 17-ethinyltestosterone, is routinely used 
for the treatment of endometriosis' and is known to suppress menstrual bleeding.* 
Endometrial effects of D are not only related to the well-known inhibition of the hypo- 
thalamic pituitary function and ovarian steroid synthesis, but they seem to be primarily 
determined by a direct action on the end~metrium.~ In fact, D binds to progesterone 
receptors (PR) and inhibits 17-P-hydroxy-steroid-dehydrogena~e~ and steroid sulfatase 
activity5 in human endometrium. The effectiveness of D in treatment of perimeno- 
pausal abnormal bleeding has been confirmed in many trials.C7 The demonstration 
of antiproliferative activity on human endometrial cancer cells in vivos and on ade- 
nomatous hyperplasia in vivo,9 together with the histologic observation that D induces 
rapid atrophic changes whereas a marked decidual reaction is found through progestin 
treatment, suggest a difference in the effect of D and typical progestins on endometrial 
tissue. In this regard we have considered useful to evaluate clinically, hysteroscopically 
and histopathologically the efficacy of D 200 mg daily for 3 months in the treatment 
of perimenopausal abnormal bleeding sustained by endometrial hyperplasia without 
cytologic atypiatO in patients at their first therapeutic approach (group A) and in 
women already treated by progestin with persistance of the disease or recurrence within 
two months (group B). In addition a further endometrial antiproliferative mechanism 
of action of D, probably in relation with its immunosuppressive activity is indirectly 
shown by means of a primary endometrial cell culture conditioned by medium from 
peritoneal macrophages cultured in vitro. 
MATERIALS AND METHODS 
Subjects and Clinical Protocols 
We have treated by 200 mg daily of D 42 patients with perimenopausal abnormal 
bleeding underlying an endometrial hyperplasia without cytologic atypia and not pre- 
viously treated (group A) and 23 women with uterine bleeding already treated by 
Norethisterone and/or Medroxyprogesterone but with a persistance or recurrence of 
symptoms within two months (group B). Each patient underwent a hysteroscopic ex- 
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amination with guided endometrial biopsy before starting treatment. The treatment 
was monitored by: 1) a subjective semiquantitative evaluation of bleeding during 
treatment and in a follow up to 12 months; 2) hysteroscopically before, at the end 
of treatment, and in a follow up to 12 months; 3) histopathologically before and after 
treatment. Side effects and adverse reactions were carefully evaluated. 
Experimental Section 
On the basis of a previous experience" in which we showed that D, at a concen- 
tration of 10-6M, significantly reduced the phagocytic ability of peritoneal macro- 
phages in vitro, we wanted to see if the steroid is able to decrease the secretion of 
growth factors12J3 by these immune cells and how such an immunosuppressive effect 
can be related to endometrial proliferation in vitro. Macrophages derived from peri- 
toneal fluid collected laparoscopically with an average yield of 5 x 10s cells/ml. Cells 
were put in RPMI medium with 5% FBS steroid free, washed, centrifuged, and re- 
suspended to a final concentration of 1 x 106 per dish using 24-well tissue culture 
plates in 1.5 ml of medium. Cultures were washed 2 hours after plating to separate 
nonadherent cells, and then incubated for 48 hours. Then supernatants were recovered 
and frozen at -80°C or immediately used. In some of these cultures, after separating 
nonadherent cells, D was added at different concentrations washing and changing 
medium 24 hours later. Then macrophages were cultured for 48 hours when super- 
natants were recovered. Endometrial cells derived from biopsy specimens sampled 
in the luteal phase and immediately put in ice-cold 1 : 1 mixture of DMEM and Ham's- 
F-12. Samples were dissected and a separation between stromal and epithelial cells 
was performed following the Osteen technique14 with some slight modifications. 15 Es- 
sentially the method was based on three consecutive incubations in medium containing 
0.5% collagenase and 0.05% DNAase followed by differential sedimentation of epi- 
thelial cells at unit gravity and by selective attachment of stromal cells to plastic cul- 
tureware. At the end of separation both epithelial and stromal cells were plated at 
a final density of 5 x lo5 cells/ml in 24-well plates in DMEM-F-12 with 10% char- 
coal extracted FBS for 48 hours (TO). Cultures were washed and incubated in medium 
with 2% steroid free FBS for 48 hours (TI). Cell counts were performed on day 2 
and day 4 of culture. At TO different amounts (1040% vol/vol) of supernatant from 
macrophage culture previously treated or not with different concentrations of D were 
added to the endometrial cell cultures. Viability of cell cultures were assessed by Trypan 
blue exclusion. 
RESULTS AND DISCUSSION 
In group A (TABLE 1) there was a subjective significant decrease of bleeding in 
38 out of 41 patients (88.2%), and this result remained unchanged (84.3%) 2 months 
after discontinuation of treatment, while 4 months after (24.9% of recurrence) and 
up to 12 months the abnormal bleeding reappeared in 56.2% of women. In TABLE 2 
is shown how in group B (patients not responding to progestins) the persistence of 
heavy blood loss at the end of treatment was 22.7%; this can be considered a very 
good result considering patients as a control for themselves. This result was practically 
unchanged 2 months later (27%), with a significant increase in recurrence at 4 (49.9%) 
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TABLE 1. Blood Loss and Days of Bleeding in Group A 
Months Posttreatment End of 
Pretreatment Treatment 2 4 up to 12 
n ('3%) n (%) n (X) n (%) n (%) 
Blood Loss 
1 (3) 2 (7) 4 (25) Flooding 19 (45) - 
Heavy 23 (55) 3 (7) 3 (9) 6 (18) 6 (31) 
33 (81) 25 (79) 18 (69) 6 (38) Normal - 
1 (8) 
Amenorrhea - 
Number of Patients 42 41 32 28 16 
Days of Bleeding 
- 
2 ( 5 )  1 (3) 1 (3) 
3 (7) 2 (8) 1 (3) 
Spotting - 
(mean * SD) 8.9 f 3.7 5.2 f 3.4 5.4 f 3.8 6.3 f 4.8 6.9 f 3.7 
and up to 12 months (55.3%). Hysteroscopically in only two patients in group A (4.8%) 
and two patients in group B (9%) did the hyperplastic picture not revert at the end 
of treatment, and one of these four patients was a false positive on the basis of the 
biopsy result (TABLE 3). The hysteroscopic follow-up showed a rapid appearance of 
hypoatrophic pictures with a progressive increase in the normal findings both prolif- 
erative and secretive, but also with a meaningful reappearance of hyperplasia up to 
60% at 4 and 12 months (TABLE 4). 
The comparison of hysteroscopic findings with histopathologic pictures shows clearly 
a good correlation with just 1 hysteroscopic false positive, 2 false negative, and 2 
not diagnostic exams (TABLE 5) .  The most interesting aspect of this comparison is 
the invaluable importance of the hysteroscopy in the diagnosis of hypoatrophia, which 
is very often undiagnosed bioptically for inadequate sampling. 
The most frequent side effects during this treatment were weight gain, muscle cramps, 
headache and acne, but in only two cases was it necessary to stop treatment (TABLE 6). 
Our data clearly show the efficacy of the regimen of D 200mg daily in the treatment 
of perimenopausal abnormal bleeding, as indicated in previous reports but 
TABLE 2. Blood Loss and Davs of Bleedine in GrouD B 
Months Posttreatment 
End of 
Pretreatment Treatment 2 4 up to 12 
n (56) n (%) n (%) n (%) n ( % )  
Blood Loss 
Flooding 8 (38) 1 ( 5 )  2 (9) 3 (17) 3 (26) 
Heavy 14 (81) 4 (18) 4 (18) 6 (33) 8 (53) 
3 (28) 14 (63) 14 (83) 8 (44) Normal - 
1 (5 )  1 (5 )  
2 (9) 1 ( 5 )  1 (6) 1 (7) Amenorrhea - 
Number of Patients 23 22 22 18 15 
Days of Bleeding 
- - Spotting - 
(mean f SD) 8 . 5 f 4 . 1  5 . 9 k 2 . 2  6 . 4 f 3 . 6  6 . 8 f 4 . 3  7 . 6 f 3 . 8  
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TABLE 3. Hysteroscopic Findings before (TO) and at the End of Treatment (TI) 
with Danazol 200 mg Daily for 3 Months 
To TI 
Hysteroscopic Group A Group B Group A Group B 
Finding n (%) n (96) n (%) n (%) 
Hyperplasia 39 (92.8) 22 (95.6) 2 (4.8) 2 (9.0) 
Hypo-atrophy - - 32 (78.0) 16 (72.7) 
Normotrophy 2 (4.7) - 6 (14.6) 4 (18.1) 
Not diagnostic 1 (2.3) 1 (4.3) I (2.4) - 
TOTAL 42 23 41 22 
TABLE 4. Hysteroscopic Follow-up at 2 Months (Tz), 4 Months (T3) and up to 12 
Months (T4) after Treatment with Danazol 200 mg Daily for 3 Months 
T2 T3 T4 
Hysteroscopic Group A Group B Group A Group B Group A GroupB 
Finding n (%) n (%) n (%) n (%) n (I) n (%) 
Hyperplasia 2 (11.1) 3 (20.0) 4 (28.5) 3 (27.2) 9 (60.0) 5 (62.5) 
Hypo-atrophy 10 (55.5) 8 (53.3) 4 (28.5) 2 (18.1) 2 (13.3) 1 (12.5) 
Normotrophy 
Proliferative 4 (22.2) 3 (50.0) 4 (28.5) 4 (36.3) 3 (20.0) 2 (25.0) 
Secretory 2 (11.1) 1 (6.6) 2 (14.2) 2 (18.1) 5 (33.3) - 
Not diagnostic - - - - - - 
TOTAL 18 15 14 11 15 8 
TABLE 5. Comparison between Hysteroscopic Findings and Histopathologic Pic- 
tures before (TO) and after Treatment (TI) 
Hysteroscopic Finding 
Histopathologic 
Appearance 
Adenomatous hyperplasia 
Glandular hyperplasia 
Gland. cystic hyperplasia 
Proliferative (a) with 
fibrotio stroma (b) 
Irregular maturation 
Atrophic 
Atrophic with stroma 
Inadequate sampling 
pseudodecidualization 
Hyper- 
plasia 
Hermo- 
trophy 
Hypo- 
atrophy 
Not 
diagnostic TOTAL 
To TI 
9 2  
21 1 
31 - 
- la 
- -  
- -  
To TI 
2 -  
- -  
- 7b 
- 2  
- 1  
- -  
- I1 - 19 
To TI 
- -  
2 -  
To TI 
9 2  
25 1 
31 - 
- 8  
- 3  
- 18 
- 12 
- 19 
TOTAL 61 4 2 10 - 48 2 1 65 63 
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TABLE 6. Side Effects during Treatment 
Month 1 Month 3 
n ( 7 % )  n ( 7 % )  
Weight gain 
Headache 
Nausea or vomiting 
Acne 
Hirsutism 
Muscle cramps 
Hot flushes 
Skin rash 
Voice change 
Edema 
Decreased breast size 
TOTAL 
7 (10.7) 
3 (4.6) 
3 (4.6) 
3 (4.6) 
1 (1.5) 
4 (6.1) 
3 (4.6) 
1 (1.5) 
1 (1.5) 
2 (3.0) 
3 (4.6) 
65 
5 (7.9) 
3 (4.7) 
4 (6.3) 
l (1 .5 )  
2 (3.1) 
3 (4.7) 
- 
- 
l (1 .5)  
4 (6.3) 
- 
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they also point out the effectiveness of this steroid in those forms not responding to 
progestins, confirming indirectly the existence of additional mechanisms of antipro- 
liferative action on the endometrium if compared to progestogens. In order to verify 
the hypothesis of an antiproliferative effect mediated by the immunosuppressive ac- 
tivity of this steroid, we have used an experimental model of primary endometrial 
cell cultures conditioned by supernatants from peritoneal macrophages cultured in 
vitro with or without D. The rationale underlying this hypothesis was to test the ability 
of D to inhibit the secretion of growth factors stimulating the endometrial proliferation 
by uterine immune cells. 
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FIGURE 1. Epithelial cells growth with the addiction of different concentration of supernatant from 
a peritoneal macrophage culture (MS). 
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FIGURE 2. Stromal cells growth with the addiction of different concentration of supernatant from 
a peritoneal macrophage culture (MS). 
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FIGURE 3. Epithelial cells with the addiction of 40% vollvol of supernatant from a peritoneal macro- 
phage culture previously treated with different concentration of Danazol. 
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Our results with this model have shown a marked increase in proliferation when 
adding to endometrial epithelial cells an aliquot of 40% in volume of supernant from 
the peritoneal macrophage culture (FIG. 1 ) .  We have used peritoneal samples as a 
source of macrophages because they can be easily collected and because they seem 
to be strictly related to the resident immune cells in human endometrium.'5 Using 
endometrial stromal cells the increase induced by macrophage supernatant was not 
so evident, probably in relation to the more active early proliferation to confluence 
of these cells in virro (FIG. 2). When we have used supernatants of macrophages pre- 
viously exposed to different concentrations of D, we have demonstrated a significant 
decrease in the proliferation with the peak at 10-6M concentration of D (FIG. 3). 
In conclusion, our clinical data strongly suggest the presence of other mechanisms 
of endometrial antiproliferative effect of D in addition to the progestin-like ones. Among 
these further mechanisms, our preliminary results using a conditioned endometrial 
primary cell culture seem to show the importance of the inhibition in the production 
of growth factors by local immune cells exerted by D. 
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